It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Complex-I-deficiency represents the most frequent pathogenetic cause of human mitochondriopathies. Therapeutic options for these neurodevelopmental life-threating disorders do not exist, partly due to the scarcity of appropriate model systems to study them. Caenorhabditis elegans is a genetically tractable model organism widely used to investigate neuronal pathologies. Here, we generate C. elegans models for mitochondriopathies and show that depletion of complex I subunits recapitulates biochemical, cellular and neurodevelopmental aspects of the human diseases. We exploit two models, nuo-5/NDUFS1- and lpd-5/NDUFS4-depleted animals, for a suppressor screening that identifies lutein for its ability to rescue animals’ neurodevelopmental deficits. We uncover overexpression of synaptic neuroligin as an evolutionarily conserved consequence of mitochondrial dysfunction, which we find to mediate an early cholinergic defect in C. elegans. We show lutein exerts its beneficial effects by restoring neuroligin expression independently from its antioxidant activity, thus pointing to a possible novel pathogenetic target for the human disease.
Mitochondrial deficiency causes rare incurable disorders. Here, the authors use C. elegans to study these diseases and find that the natural compound lutein prevents neurodevelopmental deficits, thus pointing to a possible therapeutic target for the human diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 IUF-Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany (GRID:grid.435557.5) (ISNI:0000 0004 0518 6318)
2 IUF-Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany (GRID:grid.435557.5) (ISNI:0000 0004 0518 6318); Heinrich Heine University, Institute for Clinical Chemistry and Laboratory Diagnostic, Medical Faculty, Duesseldorf, Germany (GRID:grid.411327.2) (ISNI:0000 0001 2176 9917)
3 University Children’s Hospital, Heinrich Heine University, Department of General Pediatrics, Neonatology and Pediatric Cardiology, Duesseldorf, Germany (GRID:grid.14778.3d) (ISNI:0000 0000 8922 7789)
4 Institut de Ciència de Materials de Barcelona, ICMAB-CSIC. Campus UAB, Barcelona, Spain (GRID:grid.435283.b) (ISNI:0000 0004 1794 1122)
5 Penn State College of Medicine, Department of Cellular and Molecular Physiology, Hershey, USA (GRID:grid.240473.6) (ISNI:0000 0004 0543 9901)
6 Duke University, Nicholas School of the Environment, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)